期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

地西他滨治疗高危骨髓增生异常综合征10例疗效观察 被引量：3

在线阅读 下载PDF
导出
摘要 骨髓增生异常综合征（myelodysplasticsyndrome，MDS）是一组起源于造血干细胞的获得性克隆性疾病，其特征性病理生理改变是克隆性造血干、祖细胞发育异常和无效造血，其基本临床特征是骨髓中造血细胞有发育异常的形态学表现和外周血细胞减少以及易向急性髓细胞白血病（acutemyelogenousleukemia，AML）转化。
作者 唐元艳 熊涛 梁艳 刘敏 余卓君 刘荟敏 张利铭 黄知平
机构地区 华中科技大学同济医学院附属荆州医院血液内科
出处 《临床荟萃》 CAS 2012年第19期1731-1733,共3页 Clinical Focus
关键词 骨髓增生异常综合征 治疗结果 地西他滨
分类号 R551.31 [医药卫生—血液循环系统疾病]
  • 相关文献

参考文献8

  • 1马军,王建祥,主编.造血系统疾病临床诊疗规范教程[M].北京:北京大学医学出版社,2009:548.
  • 2柯晴,岑洪,胡晓桦.去甲基化药物地西他滨治疗血液系统恶性肿瘤的研究进展[J].医学综述,2010,16(7):1068-1070. 被引量：19
  • 3赖沛龙,杜欣,翁建宇,耿素霞,王玉春,陆泽生,钟立业,邓程新,林绍泽.骨髓增生异常综合征患者地西他滨治疗后DNA甲基化水平变化[J].临床荟萃,2012,27(2):114-117. 被引量：9
  • 4Kantarjian H,Issa JP,Rosenfeld CS,et al. Deeitabine improves patient outcomes in myelodysplastic syndromes: results of a phase II[ randomized study[J]]. Cancer, 2006, 106 (8) : 1794- 1803.
  • 5Kantarjian H, Oki Y, GarciaManero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia [J]. Blood, 2007,109 ( 1 ) : 52-57.
  • 6Steensma DP, Baer MR, Slack JL, et al. Muhicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial[J]. J Clin Oneol,2009, 27(23) 3842-3848.
  • 7Liibbert M, Suciu S, Baila L, el: al. Low-dose decitabine versus best supportive care in elderly patients with intermediate-or high-risk myelodysplastie syndrome (MDS) ineligible for intensive ehemotherapy: final results of the randomized phase study of the european organisation for research and treatment of cancer leukemia group and the german MDS study group[J]. J Clin Oncol,2011,29(15) :1987-1996.
  • 8Lee JH, Jang JH, Park J, et al. A prospective multicenter observational study of decitabine treatment in Korean patients with myelodysplastic syndrome [J]. Haematologica, 2011,96 (10) : 1441-1447.

二级参考文献30

  • 1Murai M,Toyota M, Satoh A,et al. Aberrant DNA methylation associated with silencing BN IP3 gene expression in haematopoietic tumours [ J ]. Br J Cancer,2005,92 ( 6 ) : 1165-1172.
  • 2van Doom R,Zoutman WH, Dijkman R, et al. Epigenetic profiling of cutaneous T-cell lymphoma:promoter hypennethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73 [ J ]. J Clin Oncol,2005,23 ( 17 ) :3886-3896.
  • 3Hasegawa D,Manabe A,Kubota T. Methylatian status of the p15 and p16 genes in paediatric myelodysplastic syndrome and juvenile myelomonocytic leukaemia[ J]. Br J Haematol,2005,128(6) :805-812.
  • 4Zhang SJ, Endo S, Saito T, et al. Primary malignant lymphoma of the brain:frequent abnormalities and inactivation of p14 tumor suppressor zene[ J]. Cancer Sci ,2005,96 (1) :38-41.
  • 5Santini V, Kantarjian HM,Issa JP. Changes in DNA methylation in neoplasia : pathophysiology and therapeutic implications [ J ]. Ann Intern Med,2001,134(7) :573-586.
  • 6Claus R, Lubbert M. Epigenetie targets in hematopoietic malignancies[J]. Oneogene,2003,22(42) :6489-6496.
  • 7Shen L,Toyota M, Kondo Y, et al. Aberrant DNA methylation of p57KIP2 identifies a cell cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia [J].Blood,2003,101 (10) :4131-4136.
  • 8Toyota M, Kopecky K J, Toyota MO, et al. Methylation profiling in acute myeloid leukemia[ J]. Blood,2001,97(9) :2823-2829.
  • 9Issa JP, Gharibyan V, Cortes J, et al. Phase Ⅱ study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate [ J ]. J Clin Oneol,2005,23 ( 17 ) :3948-3956.
  • 10Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-20-deoxyeytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome : a nmhieenter phase Ⅱ study in elderly patients [ J ]. J Clin Oncol,2000,18 ( 5 ) : 956 -962.

共引文献32

同被引文献23

引证文献3

二级引证文献23

临床荟萃
2012年 第19期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部